AGO2 and prostate cancer: The FRRS1 gene exhibits NMD insensitivity in one experiment (GSE16170) using two treatments (Ago2 siRNA - targets CBP80/20-bound mRNAs and thus considered a regulator of NMD and UPF1 and Ago2 siRNA), and NMD sensitivity in another experiment, in mononuclear leukocytes of prostate cancer patients but not of healthy patients (GSE24204).